The abstract is read at the publisher; the summary is JClub's.
mRNA-1010 may prevent an additional 21,100 influenza-related hospitalizations versus HD-IIV among US adults aged ≥65 years over one year.
- Why it matters: Older adults face high risk of severe influenza outcomes, and egg-based HD-IIV may be affected by egg-adapted mutations.
- What they did: A decision-analytic model projected one-year influenza burden using CDC-based coverage, HD-IIV vaccine effectiveness, and epidemiology, with mRNA-1010 relative VE informed by clinical trial data and published egg-adaptation effects.
- The result: Compared with HD-IIV, mRNA-1010 may avert 232,200 symptomatic infections, 130,000 outpatient cases, and 2,200 influenza-related deaths, with prevented outcomes most sensitive to influenza incidence and VE.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.